Yan-Fang Liu

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Venues

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)

Yan-Fang Liu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yan-Fang Liu